Clinically, PCa tumours with inhibition of both tumour suppressor phosphatases PTEN (genetic deletion) and PP2A (PME‐1 overexpression) had remarkably short relapse‐free survival introducing PME‐1 as a potential clinically applicable PCa biomarker. The gene discussed is PPME1; the disease is posterior cortical atrophy.